Intrathecal Cytarabine, Methotrexate, and Hydrocortisone for the Prevention of High-Grade Chimeric Antigen Receptor T-Cell-Associated Neurotoxicity Syndrome (NCT06895473)
A Phase 2 Study of Prophylactic IT Chemotherapy to Prevent High-Grade Chimeric Antigen Receptor (CAR) T-Cell-Associated Neurotoxicity Syndrome
🩺 Plain-English Summary (8th-Grade Level)
This phase II trial tests how well cytarabine (Ara-C), methotrexate, and hydrocortisone given between the spinal cord and the membranes that protect it (intrathecal \[IT\]) works in preventing high-grade immune effector-associated neurotoxicity syndrome (ICANS) in patients receiving chimeric antigen receptor (CAR) T-cell therapy. ICANS is a challenging complication of CAR T-cell therapy that causes neurological effects varying from mild headaches or temporary confusion to hallucinations, swelling in the brain, and seizures. Between 20%-70% of patients receiving CAR T-cell therapy show symptoms of neurotoxicity.
Who can join: Review the eligibility criteria below.
Location: OHSU Knight Cancer Institute — Portland, Oregon
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (1 Sites)
- OHSU Knight Cancer Institute — Portland, Oregon
📞 Contact the Study Coordinator
Phone: (503) 494-8950
Email: spurgeos@ohsu.edu
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Hematopoietic and Lymphatic System Neoplasm
- Evaluation of Broccoli Seed and Sprout Extract for Detoxification of Carcinogens in Firefighters — Tucson, Arizona
- Bupropion to Reduce Cancer Related Fatigue in Cancer Survivors — Anchorage, Alaska
- Virtual Reality for Symptom Management in Patients Undergoing Hematopoietic Stem Cell Transplantation — Buffalo, New York
- Data-Driven Strategies for Patient Engagement About Cancer Clinical Trials — Los Angeles, California
- Improving Adolescent and Young Adult Self-Reported Data in ECOG-ACRIN Trials — Fairbanks, Alaska
- On the BRINK: PhotoBiomodulation (PBM) for Mucositis in Patients Undergoing Allogeneic Hematopoietic Stem Cell TRansplant (HSCT) - Implementing the Evidence & Discovering New Knowledge — Duarte, California
Explore by condition: All Hematopoietic and Lymphatic System Neoplasm clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.